Lanean...

Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis

Optimal salvage therapy for refractory HLH is unknown. In our patient, ruxolitinib treatment led to clinical remission of refractory HLH.

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Blood Adv
Egile Nagusiak: Broglie, Larisa, Pommert, Lauren, Rao, Sridhar, Thakar, Monica, Phelan, Rachel, Margolis, David, Talano, Julie
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2017
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728466/
https://ncbi.nlm.nih.gov/pubmed/29296794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017007526
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!